Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy.

Abstract

Reactivation of hepatitis B virus (HBV) infection is a frequent complication of cytotoxic chemotherapy that includes steroids. International studies have shown that lamivudine reduces the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy to treat malignancies. However, prolonged lamivudine therapy is associated with an increased risk of drug-resistant tyrosine-methionine-aspartate-aspartate (YMDD) mutations. Here, we studied the role of entecavir in preventing morbidity and mortality associated with HBV reactivation. Three patients with both solid malignancies and hepatitis B surface antigen-positive hepatitis B underwent cytotoxic chemotherapy with steroids. They were followed up for at least 6 months after the completion of chemotherapy. The chemotherapeutic regimens comprised carboplatin and paclitaxel for non-small-cell lung cancer, and docetaxel monotherapy or cyclophosphamide plus epirubicin for breast cancer, respectively. All patients completed chemotherapy with steroids without developing severe hepatitis that could be attributable to HBV reactivation. Entecavir prevented the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy for malignancies. Although further studies are required to evaluate whether entecavir can prevent the increased risk of YMDD mutation and decrease the rates of disrupted chemotherapy due to severe hepatitis more effectively than lamivudine, entecavir should be considered before lamivudine for such patients.

• Authors: Riki Okita, Mamoru Takahashi, Hiroyuki Narahara, Yuichi Sanada, Morihito Okada, Yoshiiku Kawakami, Kazuaki Chayama, Kiwamu Okita
• Journal: Clinical journal of gastroenterology (Clin J Gastroenterol) Vol. 2 Issue 3 Pg. 214-217 (Jun 2009) ISSN: 1865-7257 [Print] Japan
• PMID: 26192299 (Publication Type: Journal Article)